Connect with us

News

China’s New Cancer drug is Approved in the US But Will Cost 30 Times More

China’s New Cancer drug is Approved in the US But Will Cost 30 Times More

(CTN News) – Two other cancer medications created by Chinese scientists are also expected to face price increases in the US market, with one drug costing more than 30 times more than in China. The FDA just authorized the drug.

Chinese cancer medications will be priced much lower than American equivalents, even after accounting for the enormous markup in the US market.

The pricing of Loqtorzi, the US brand name for Toripalimab, was released on Monday by California-based Coherus Biosciences and Shanghai Junshi Biosciences, the drug’s marketing partners.

According to Chinese cancer informational websites, the cost of a single-dose vial of Toripalimab is approximately 2,000 yuan (US$280) in China.

In a Monday filing to the US Securities and Exchange Commission, Coherus announced that the wholesale cost of a single-dose vial in the US will be $8,892.03. Compared to the same drug sold in China, the price in the US is over 31 times higher.

Even with the price increase, FiercePharma estimates it will be 20% cheaper than Keytruda, the best-selling PD-1 antibody medication in the US. PD-1 inhibitors help keep the immune system in balance.

The drug’s retail price in China is different from its national healthcare insurance enrollment price.

National Medical Insurance Administration data shows that by year’s end, nearly all Chinese citizens (95 percent) had enrolled in the system and gained basic coverage.

Like the black market for cocaine, the drug price has skyrocketed. According to US media, the street value in the US is forty times higher than in Colombia, the drug’s country of origin.

This month, the FDA approved two additional cancer medications developed in China for distribution in the US, after Toripalimab’s clearance.

The Chinese biotech company HutchMed’s oral medicine fruquintinib was approved for the treatment of persons with metastatic colorectal cancer who have already received treatment for the disease on November 9.

To treat chemotherapy-induced neutropenia, or low levels of a type of white blood cells, Evive Biotech—a worldwide biopharma subsidiary of Yifan Pharmaceutical based in Hangzhou—developed the injectable medication efbemalenograstim alfa. On November 16, the drug was approved for use.

Just as Toripalimab, fruquintinib—which will be sold in the US by the Tokyo-based Takeda Pharmaceutical Company under the brand name Fruzaqla—will also experience a price increase.

According to Medical Valley, a Chinese medical news site, a box of 21 pills containing 5mg of the medicine is offered in China for approximately 7,500 yuan (US$1,050). The identical dosage, according to a Takeda prescription, will cost $25,200 at wholesale in the United States, which is twenty-four times more than the cost in China.

A study released last year in the Journal of the American Medical Association cast doubt on the assertion made by US pharma corporations that the high cost of research and development is the driving force behind the country’s medicine prices.

In spite of the fact that the United States pays the most for innovative pharmaceuticals, the study found that the government health insurance program in the nation has never been able to negotiate lower rates.

From 2009 to 2018, the authors examined 60 medications, or 20% of all drugs approved. They discovered no correlation between the reported prices of these treatments and their estimated research expenses.

The study concluded that drug corporations set their prices based on market demand. This is affected by the drug’s demand, whether patients need to take it continually, and the market competition level.

After Toripalimab’s approval, many wondered if the medicine would be sold at a steep discount compared to its primary US market rival.

This ensued after pharmaceutical behemoth Eli Lilly made a 40% discount promise for their Chinese PD-1 drug that they were requesting FDA clearance for.

However, as reported by FiercePharma, Coherus CEO Dennis Lanfear stated on an investor call following Toripalimab’s approval that such a “heavily” discounted price was not being considered.

According to FiercePharma, Keytruda, the major competitor to Toripalimab available in China, was listed at half the price it is in the US when it first entered the market. Merck & Co. is situated in New Jersey.

Fruquintinib, an oral medicine, is the first chemotherapy-free treatment option for individuals with metastatic colorectal cancer in more than ten years. It is prescribed to patients with advanced stages of the disease. The NMPA, China’s national medical products agency, gave its initial green light to it in 2018.

The American Cancer Society reports that colorectal cancer, which starts in the colon or rectum, is the third most frequent cancer in the United States and the third greatest cause of cancer-related deaths for both men and women. According to a news release from Takeda regarding the medicine, colorectal cancer was ranked third globally.

“There has been limited innovation for patients with metastatic colorectal cancer for more than a decade,” stated Teresa Bitetti, president of global oncology business at Takeda.

Colorectal cancer is responsible for 7.8% of all new cancer diagnoses in the United States. Takeda reports that 70% of colorectal cancer patients will have metastasis, which occurs when malignant growths extend beyond the colon and rectum.

According to Cathy Eng, a doctor at Vanderbilt University Medical Centre, “metastatic cancer patients often present with inoperable disease… we must evaluate and consider treatment options that will improve overall survival without compromising quality of life” (hutchMed, 2019).

Fruquintinib was approved after two trials that included over 1,000 individuals. Patients in the studies who received both the medicine and supportive care had twice the progression-free survival rate than those who received only supportive care or a placebo.

Takeda reported a 34% reduction in mortality risk in patients treated with Fruquintinib. The Food and Drug Administration reported that hypertension was the medication’s most common side effect, followed by hand-foot syndrome and increased protein in the urine.

Other businesses own the rights to sell the three Chinese medications that the FDA approved this month in the US.

According to HutchMed, they will get royalties on net sales and other payments if the drug hits major milestones, while Takeda will manufacture and commercialize Fruquintinib outside of China.

Acrotech Biopharma of New Jersey claims that its drug efbemalenograstim alfa, which will be sold in the United States under the brand name Ryzneuta, can help avoid the negative effects of low neutrophil numbers.

Patients are more likely to get infections when their neutrophil count is low; the CDC reports that chemotherapy-induced neutrophil count drops often occur in the weeks following treatment.

Acrotech reported that the medicine, licensed by the NMPA in May in China, has been tested in 12 clinical trials with over 1,200 patients worldwide. The results show that the treatment effectively reduces the time patients spend with extremely low neutrophil levels.

Biotech company BeiGene co-founder Wang Xiaodong predicted earlier this month at the Hong Kong Laureate Forum that China will spearhead an explosion in the study of novel medications.

As far as the West is concerned, China is already well ahead. “Chinese companies will produce even more of a product if it is available overseas,” Wang stated.

News

Trudeau’s Gun Grab Could Cost Taxpayers a Whopping $7 Billion

Trudeau's Gun Grab
Trudeau plans to purchase 2,063 firearm from legal gun owners in Canada - Rebel News Image

A recent report indicates that since Trudeau’s announcement of his gun buyback program four years ago, almost none of the banned firearms have been surrendered.

The federal government plans to purchase 2,063 firearm models from retailers following the enactment of Bill C-21, which amends various Acts and introduces certain consequential changes related to firearms. It was granted royal assent on December 15 of last year.

This ban immediately criminalized the actions of federally-licensed firearms owners regarding the purchase, sale, transportation, importation, exportation, or use of hundreds of thousands of rifles and shotguns that were previously legal.

The gun ban focused on what it termed ‘assault-style weapons,’ which are, in reality, traditional semi-automatic rifles and shotguns that have enjoyed popularity among hunters and sport shooters for over a century.

In May 2020, the federal government enacted an Order-in-Council that prohibited 1,500 types of “assault-style” firearms and outlined specific components of the newly banned firearms. Property owners must adhere to the law by October 2023.

Trudeau’s Buyback Hasn’t Happened

“In the announcement regarding the ban, the prime minister stated that the government would seize the prohibited firearms, assuring that their lawful owners would be ‘grandfathered’ or compensated fairly.” “That hasn’t happened,” criminologist Gary Mauser told Rebel News.

Mauser projected expenses ranging from $2.6 billion to $6.7 billion. The figure reflects the compensation costs amounting to $756 million, as outlined by the Parliamentary Budget Office (PBO).

“The projected expenses for gathering the illegal firearms are estimated to range from $1.6 billion to $7 billion.” “This range estimate increases to between $2.647 billion and $7 billion when compensation costs to owners are factored in,” Mauser stated.

Figures requested by Conservative MP Shannon Stubbs concerning firearms prohibited due to the May 1, 2020 Order In Council reveal that $72 million has been allocated to the firearm “buyback” program, yet not a single firearm has been confiscated to date.

In a recent revelation, Public Safety Canada disclosed that the federal government allocated a staggering $41,094,556, as prompted by an order paper question from Conservative Senator Don Plett last September, yet yielded no tangible outcomes.

An internal memo from late 2019 revealed that the Liberals projected their politically motivated harassment would incur a cost of $1.8 billion.

Enforcement efforts Questioned

By December 2023, estimates from TheGunBlog.ca indicate that the Liberals and RCMP had incurred or were responsible for approximately $30 million in personnel expenses related to the enforcement efforts. The union representing the police service previously stated that the effort to confiscate firearms is a “misdirected effort” aimed at ensuring public safety.

“This action diverts crucial personnel, resources, and funding from tackling the more pressing and escalating issue of criminal use of illegal firearms,” stated the National Police Federation (NPF).

The Canadian Sporting Arms & Ammunition Association (CSAAA), representing firearms retailers, has stated it will have “zero involvement” in the confiscation of these firearms. Even Canada Post held back from providing assistance due to safety concerns.

The consultant previously assessed that retailers are sitting on almost $1 billion worth of inventory that cannot be sold or returned to suppliers because of the Order-In-Council.

“Despite the ongoing confusion surrounding the ban, after four years, we ought to be able to address one crucial question.” Has the prohibition enhanced safety for Canadians? Mauser asks.

Illegally Obtained Firearms are the Problem

Statistics Canada reports a 10% increase in firearm-related violent crime between 2020 and 2022, rising from 12,614 incidents to 13,937 incidents. In that timeframe, the incidence of firearm-related violent crime increased from 33.7 incidents per 100,000 population in 2021 to 36.7 incidents the subsequent year.

“This marks the highest rate documented since the collection of comparable data began in 2009,” the criminologist explains.

Supplementary DataData indicates that firearm homicides have risen since 2020. “The issue lies not with lawfully-held firearms,” Mauser stated.

Firearms that have been banned under the Order-in-Council continue to be securely stored in the safes of their lawful owners. The individuals underwent a thorough vetting process by the RCMP and are subject to nightly monitoring to ensure there are no infractions that could pose a risk to public safety.

“The firearms involved in homicides were seldom legally owned weapons wielded by their rightful owners,” Mauser continues. The number of offenses linked to organized crime has surged from 4,810 in 2016 to a staggering 13,056 in 2020.

“If those in power … aim to diminish crime and enhance public safety, they ought to implement strategies that effectively focus on offenders and utilize our limited tax resources judiciously to reach these objectives,” he stated.

Related News:

Millennials in Canada Have Turned their Backs on Justin Trudeau

Millennials in Canada Have Turned their Backs on Justin Trudeau

 

 

Continue Reading

News

Google’s Search Dominance Is Unwinding, But Still Accounting 48% Search Revenue

Google

Google is so closely associated with its key product that its name is a verb that signifies “search.” However, Google’s dominance in that sector is dwindling.

According to eMarketer, Google will lose control of the US search industry for the first time in decades next year.

Google will remain the dominant search player, accounting for 48% of American search advertising revenue. And, remarkably, Google is still increasing its sales in the field, despite being the dominating player in search since the early days of the George W. Bush administration. However, Amazon is growing at a quicker rate.

google

Google’s Search Dominance Is Unwinding

Amazon will hold over a quarter of US search ad dollars next year, rising to 27% by 2026, while Google will fall even more, according to eMarketer.

The Wall Street Journal was first to report on the forecast.

Lest you think you’ll have to switch to Bing or Yahoo, this isn’t the end of Google or anything really near.

Google is the fourth-most valued public firm in the world. Its market worth is $2.1 trillion, trailing just Apple, Microsoft, and the AI chip darling Nvidia. It also maintains its dominance in other industries, such as display advertisements, where it dominates alongside Facebook’s parent firm Meta, and video ads on YouTube.

To put those “other” firms in context, each is worth more than Delta Air Lines’ total market value. So, yeah, Google is not going anywhere.

Nonetheless, Google faces numerous dangers to its operations, particularly from antitrust regulators.

On Monday, a federal judge in San Francisco ruled that Google must open up its Google Play Store to competitors, dealing a significant blow to the firm in its long-running battle with Fortnite creator Epic Games. Google announced that it would appeal the verdict.

In August, a federal judge ruled that Google has an illegal monopoly on search. That verdict could lead to the dissolution of the company’s search operation. Another antitrust lawsuit filed last month accuses Google of abusing its dominance in the online advertising business.

Meanwhile, European regulators have compelled Google to follow tough new standards, which have resulted in multiple $1 billion-plus fines.

google

Pixa Bay

Google’s Search Dominance Is Unwinding

On top of that, the marketplace is becoming more difficult on its own.

TikTok, the fastest-growing social network, is expanding into the search market. And Amazon has accomplished something few other digital titans have done to date: it has established a habit.

When you want to buy anything, you usually go to Amazon, not Google. Amazon then buys adverts to push companies’ products to the top of your search results, increasing sales and earning Amazon a greater portion of the revenue. According to eMarketer, it is expected to generate $27.8 billion in search revenue in the United States next year, trailing only Google’s $62.9 billion total.

And then there’s AI, the technology that (supposedly) will change everything.

Why search in stilted language for “kendall jenner why bad bunny breakup” or “police moving violation driver rights no stop sign” when you can just ask OpenAI’s ChatGPT, “What’s going on with Kendall Jenner and Bad Bunny?” in “I need help fighting a moving violation involving a stop sign that wasn’t visible.” Google is working on exactly this technology with its Gemini product, but its success is far from guaranteed, especially with Apple collaborating with OpenAI and other businesses rapidly joining the market.

A Google spokeswoman referred to a blog post from last week in which the company unveiled ads in its AI overviews (the AI-generated text that appears at the top of search results). It’s Google’s way of expressing its ability to profit on a changing marketplace while retaining its business, even as its consumers steadily transition to ask-and-answer AI and away from search.

google

Google has long used a single catchphrase to defend itself against opponents who claim it is a monopoly abusing its power: competition is only a click away. Until recently, that seemed comically obtuse. Really? We are going to switch to Bing? Or Duck Duck Go? Give me a break.

But today, it feels more like reality.

Google is in no danger of disappearing. However, every highly dominating company faces some type of reckoning over time. GE, a Dow mainstay for more than a century, was broken up last year and is now a shell of its previous dominance. Sears declared bankruptcy in 2022 and is virtually out of business. US Steel, long the foundation of American manufacturing, is attempting to sell itself to a Japanese corporation.

Could we remember Google in the same way that we remember Yahoo or Ask Jeeves in decades? These next few years could be significant.

SOURCE | CNN

Continue Reading

News

The Supreme Court Turns Down Biden’s Government Appeal in a Texas Emergency Abortion Matter.

Supreme Court

(VOR News) – A ruling that prohibits emergency abortions that contravene the Supreme Court law in the state of Texas, which has one of the most stringent abortion restrictions in the country, has been upheld by the Supreme Court of the United States. The United States Supreme Court upheld this decision.

The justices did not provide any specifics regarding the underlying reasons for their decision to uphold an order from a lower court that declared hospitals cannot be legally obligated to administer abortions if doing so would violate the law in the state of Texas.

Institutions are not required to perform abortions, as stipulated in the decree. The common populace did not investigate any opposing viewpoints. The decision was made just weeks before a presidential election that brought abortion to the forefront of the political agenda.

This decision follows the 2022 Supreme Court ruling that ended abortion nationwide.

In response to a request from the administration of Vice President Joe Biden to overturn the lower court’s decision, the justices expressed their disapproval.

The government contends that hospitals are obligated to perform abortions in compliance with federal legislation when the health or life of an expectant patient is in an exceedingly precarious condition.

This is the case in regions where the procedure is prohibited. The difficulty hospitals in Texas and other states are experiencing in determining whether or not routine care could be in violation of stringent state laws that prohibit abortion has resulted in an increase in the number of complaints concerning pregnant women who are experiencing medical distress being turned away from emergency rooms.

The administration cited the Supreme Court’s ruling in a case that bore a striking resemblance to the one that was presented to it in Idaho at the beginning of the year. The justices took a limited decision in that case to allow the continuation of emergency abortions without interruption while a lawsuit was still being heard.

In contrast, Texas has been a vocal proponent of the injunction’s continued enforcement. Texas has argued that its circumstances are distinct from those of Idaho, as the state does have an exemption for situations that pose a significant hazard to the health of an expectant patient.

According to the state, the discrepancy is the result of this exemption. The state of Idaho had a provision that safeguarded a woman’s life when the issue was first broached; however, it did not include protection for her health.

Certified medical practitioners are not obligated to wait until a woman’s life is in imminent peril before they are legally permitted to perform an abortion, as determined by the state supreme court.

The state of Texas highlighted this to the Supreme Court.

Nevertheless, medical professionals have criticized the Texas statute as being perilously ambiguous, and a medical board has declined to provide a list of all the disorders that are eligible for an exception. Furthermore, the statute has been criticized for its hazardous ambiguity.

For an extended period, termination of pregnancies has been a standard procedure in medical treatment for individuals who have been experiencing significant issues. It is implemented in this manner to prevent catastrophic outcomes, such as sepsis, organ failure, and other severe scenarios.

Nevertheless, medical professionals and hospitals in Texas and other states with strict abortion laws have noted that it is uncertain whether or not these terminations could be in violation of abortion prohibitions that include the possibility of a prison sentence. This is the case in regions where abortion prohibitions are exceedingly restrictive.

Following the Supreme Court’s decision to overturn Roe v. Wade, which resulted in restrictions on the rights of women to have abortions in several Republican-ruled states, the Texas case was revisited in 2022.

As per the orders that were disclosed by the administration of Vice President Joe Biden, hospitals are still required to provide abortions in cases that are classified as dire emergency.

As stipulated in a piece of health care legislation, the majority of hospitals are obligated to provide medical assistance to patients who are experiencing medical distress. This is in accordance with the law.

The state of Texas maintained that hospitals should not be obligated to provide abortions throughout the litigation, as doing so would violate the state’s constitutional prohibition on abortions. In its January judgment, the 5th United States Circuit Court of Appeals concurred with the state and acknowledged that the administration had exceeded its authority.

SOURCE: AP

SEE ALSO:

Could Last-Minute Surprises Derail Kamala Harris’ Campaign? “Nostradamus” Explains the US Poll.

Scientists Awarded MicroRNA The Nobel Prize in Medicine.

US Inflation will Comfort a Fed Focused on Labor Markets.

Continue Reading

Trending